Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/TP.0000000000001537 http://scihub22266oqcxt.onion/10.1097/TP.0000000000001537 C5837069!5837069!27764033     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Transplantation 2017 ; 101 (2): e49-56 Nephropedia Template TP {{tp|p=27764033|t=2017. Underlying Mechanisms of Protection Involved in Immunocloak |pdf=|usr=}}{{27764033}} gab.com Text Underlying Mechanisms of Protection Involved in Immunocloak JO: Transplantation http://www.kidney.de/pget.php?&tw=1&pmid=27764033 #FOAvip Background: We have previously reported on a novel organ-specific immunomodifying therapy that provides protection from early allograft rejection in the absence of systemic immunosuppressive drugs. This novel therapy is a nano-barrier membrane called ImmunoCloak, consisting of a matrix of laminin, proteoglycans, fibronectin and collagens. The membrane ?immunocloaks? the luminal surfaces within the renal vasculature by covering the point of contact between donor vascular endothelial cells and the recipient?s immune cells; without adversely affecting renal function. The resulting nonthrombogenic and nonimmunogenic apical surface significantly delays the onset of rejection 5-fold over untreated controls. Currently, our focus is to elucidate the mechanisms of protection provided by placement of the membrane. Methods: The mechanisms underlying the protective effect of the ImmunoCloak treatment was evaluated using human peripheral blood mononuclear cells and by testing for antigen presentation by cytokine/chemokine analysis using the Luminex platform, T cell allogeneic responses were measured by flow cytometry and diapedesis was assessed using transwell plates. Results: We now report that ImmunoCloak interrupts antigen presentation thereby preventing early T cell activation and interferes with diapedesis. There was significant inhibition in the synthesis of proinflammatory cytokines with a concordant blockade of T cell mediated responses. The placement of the ImmunoCloak also significantly reduced leukocyte migration through the endothelial cell layer by 93%. Conclusion: Eliminating the need for nephrotoxic immunosuppressive drugs during the early posttransplant period could help to ameliorate the severity of delayed graft function and could provide a path to utilizing more ischemically damaged renal allografts. Twit Text FOAVip Underlying Mechanisms of Protection Involved in Immunocloak ????Transplantation http://www.kidney.de/pget.php?&tw=1&pmid=27764033 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27764033 #FOAvip English Wikipedia <ref>{{Cite pmid|27764033}}</ref> Underlying Mechanisms of Protection Involved in Immunocloak #MMPMID27764033 Brasile L; Henry N; Stubenitsky B Transplantation 2017[Feb]; 101 (2): e49-56 PMID27764033show ga Background: We have previously reported on a novel organ-specific immunomodifying therapy that provides protection from early allograft rejection in the absence of systemic immunosuppressive drugs. This novel therapy is a nano-barrier membrane called ImmunoCloak, consisting of a matrix of laminin, proteoglycans, fibronectin and collagens. The membrane ?immunocloaks? the luminal surfaces within the renal vasculature by covering the point of contact between donor vascular endothelial cells and the recipient?s immune cells; without adversely affecting renal function. The resulting nonthrombogenic and nonimmunogenic apical surface significantly delays the onset of rejection 5-fold over untreated controls. Currently, our focus is to elucidate the mechanisms of protection provided by placement of the membrane. Methods: The mechanisms underlying the protective effect of the ImmunoCloak treatment was evaluated using human peripheral blood mononuclear cells and by testing for antigen presentation by cytokine/chemokine analysis using the Luminex platform, T cell allogeneic responses were measured by flow cytometry and diapedesis was assessed using transwell plates. Results: We now report that ImmunoCloak interrupts antigen presentation thereby preventing early T cell activation and interferes with diapedesis. There was significant inhibition in the synthesis of proinflammatory cytokines with a concordant blockade of T cell mediated responses. The placement of the ImmunoCloak also significantly reduced leukocyte migration through the endothelial cell layer by 93%. Conclusion: Eliminating the need for nephrotoxic immunosuppressive drugs during the early posttransplant period could help to ameliorate the severity of delayed graft function and could provide a path to utilizing more ischemically damaged renal allografts. äUnderlying Mechanisms of Protection Involved in Immunocloak (epmc).pdf DeepDyve Pubget Overpricing